Compare MRVI & UROY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | UROY |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.0M | 601.8M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | UROY |
|---|---|---|
| Price | $4.82 | $3.51 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 2.5M |
| Earning Date | 05-07-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | $279.20 |
| Revenue Next Year | $7.87 | N/A |
| P/E Ratio | ★ N/A | $1,584.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $2.13 |
| 52 Week High | $5.00 | $5.52 |
| Indicator | MRVI | UROY |
|---|---|---|
| Relative Strength Index (RSI) | 68.22 | 43.31 |
| Support Level | $3.27 | $3.15 |
| Resistance Level | $5.00 | $4.07 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 81.91 | 12.39 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.